{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:02:52Z","timestamp":1779814972593,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjcard.2026.02.033","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:21:34Z","timestamp":1772209294000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients"],"prefix":"10.1016","volume":"268","author":[{"given":"Abhishek","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Creechan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waiel","family":"Abusnina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Rappaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cellamare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder D.","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell F.","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsik","family":"Ben-Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9226","authenticated-orcid":false,"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.02.033_bib0001","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.carrev.2016.10.005","article-title":"A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: a network meta-analysis","volume":"18","author":"Westman","year":"2017","journal-title":"Cardiovasc Revascularization Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0003","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2025.07.022","article-title":"Bailout use of cangrelor during percutaneous coronary intervention and associated outcomes","author":"Chaturvedi","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0005","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jcin.2024.03.010","article-title":"Evaluation of the REDUCE-CLOT study","volume":"17","author":"Shlofmitz","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.carrev.2025.04.031","article-title":"Evaluation of the REDUCtion of thrombus burdEn with core lab OcT assessmenT (REDUCE-CLOTT) study","author":"Galo","year":"2025","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0007","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0008","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with Cangrelor during PCI on Ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0009","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous Platelet Blockade with Cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2016.11.017","article-title":"Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0011","article-title":"Risk of bleeding among cangrelor-treated patients administered upstream P2Y(12) inhibitor therapy: the CAMEO registry","volume":"3","author":"Rymer","year":"2024","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0012","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0013","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1161\/CIRCULATIONAHA.111.032433","article-title":"Bleeding academic research consortium consensus report: the food and drug administration perspective","volume":"123","author":"Hicks","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0014","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1161\/01.CIR.92.10.2811","article-title":"Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global use of strategies to open occluded coronary arteries","volume":"92","author":"Gore","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0016","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0017","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0018","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","article-title":"Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX trial","volume":"9","author":"Abtan","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0019","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","article-title":"Cangrelor with and without glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"JACC"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jacc.2016.11.020","article-title":"Cangrelor: the paradox of choice","volume":"69","author":"Brar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133280","article-title":"Gender disparities in cangrelor usage for the treatment of patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"432","author":"Abusnina","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0022","first-page":"1188","article-title":"Lack of racial disparities in cangrelor therapy in patients presenting with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"105","author":"Abusnina","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ehjcvp\/pvaf002","article-title":"Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial","volume":"11","author":"Domei","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37084-2","article-title":"Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry","volume":"13","author":"Pepe","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40256-023-00616-2","article-title":"Safety and efficacy of cangrelor in acute coronary syndromes: a systematic review and network meta-analysis","volume":"24","author":"Mostafa","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish coronary angiography and angioplasty registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0027","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024513","article-title":"Cangrelor use patterns and transition to oral P2Y(12) inhibitors among patients with myocardial infarction: initial results from the cameo registry","volume":"11","author":"Rymer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0029","doi-asserted-by":"crossref","first-page":"oead076","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study","volume":"3","author":"De Luca","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.amjcard.2026.02.033_bib0030","article-title":"Cangrelor use patterns and transition to oral P2Y","volume":"11","author":"Rymer","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:08:51Z","timestamp":1779811731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S0002914926000822"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.02.033","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}